

KERYX BIOPHARMACEUTICALS INC

Form POS AM

December 13, 2018

**As filed with the Securities and Exchange Commission on December 13, 2018**

**Registration No. 333-111143**

**Registration No. 333-113654**

**Registration No. 333-114593**

**Registration No. 333-119376**

**Registration No. 333-126494**

**Registration No. 333-130809**

**Registration No. 333-133051**

**Registration No. 333-161607**

**Registration No. 333-171517**

**Registration No. 333-186332**

**Registration No. 333-190353**

**Registration No. 333-201605**

**Registration No. 333-201639**

**Registration No. 333-214513**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-111143**

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-113654**  
**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-114593**  
**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-119376**  
**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-126494**  
**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-130809**  
**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-133051**  
**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-161607**  
**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-171517**  
**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-186332**  
**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-190353**  
**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-201605**  
**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-201639**  
**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-214513**

**REGISTRATION STATEMENT**

***UNDER***

***THE SECURITIES ACT OF 1933***

**KERYX BIOPHARMACEUTICALS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction of**  
**incorporation)**

**One Marina Park Drive, 12th Floor**

**13-4087132**  
**(I.R.S. Employer**  
**Identification Number)**

**Boston, Massachusetts 02210**

**Telephone: (617) 466-3500**

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)**

**Nicole R. Hadas**

**President and Secretary**

**Keryx Biopharmaceuticals, Inc.**

**245 First Street**

**Cambridge, Massachusetts 02142**

**(617) 871-2098**

**(Name, address, including zip code, and telephone number, including area code, of agent for service)**

*Copy to:*

**Peter Handrinos, Esq.**

**R. Scott Shean, Esq.**

**Daniel Rees, Esq.**

**Latham & Watkins LLP**

**200 Clarendon Street**

**Boston, Massachusetts 20116**

**(617) 948-6000**

**Approximate date of commencement of proposed sale to the public:**

**Not applicable.**

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box.

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form POS AM

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act (Check one):

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act.

## DEREGISTRATION OF UNSOLD SECURITIES

Keryx Biopharmaceuticals, Inc., a Delaware corporation (the Company ), is filing this (i) Post-Effective Amendment No. 1 to the Registration Statement on Form S-3 (File No. 333-111143), (ii) Post-Effective Amendment No. 1 to the Registration Statement on Form S-3 (File No. 333-113654), (iii) Post-Effective Amendment No. 1 to the Registration Statement on Form S-3 (File No. 333-114593), (iv) Post-Effective Amendment No. 1 to the Registration Statement on Form S-3 (File No. 333-119376), (v) Post-Effective Amendment No. 1 to the Registration Statement on Form S-3 MEF (File No. 333-126494), (vi) Post-Effective Amendment No. 1 to the Registration Statement on Form S-3 (File No. 333-130809), (vii) Post-Effective Amendment No. 1 to the Registration Statement on Form S-3 (File No. 333-133051), (viii) Post-Effective Amendment No. 1 to the Registration Statement on Form S-3 (File No. 333-161607), (ix) Post-Effective Amendment No. 1 to the Registration Statement on Form S-3 (File No. 333-171517), (x) Post-Effective Amendment No. 1 to the Registration Statement on Form S-3 MEF (File No. 333-186332), (xi) Post-Effective Amendment No. 1 to the Registration Statement on Form S-3 (File No. 333-190353), (xii) Post-Effective Amendment No. 1 to the Registration Statement on Form S-3 ASR (File No. 333-201605), (xiii) Post-Effective Amendment No. 1 to the Registration Statement on Form S-3 MEF (File No. 333-201639), and (xiv) Post-Effective Amendment No. 1 to the Registration Statement on Form S-3 (File No. 333-214513) (collectively, the Prior Registration Statements ).

On June 28, 2018, the Company entered into an Agreement and Plan of Merger (the Merger Agreement ) with Akebia Therapeutics, Inc., a Delaware corporation ( Akebia ), and Alpha Therapeutics Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Akebia ( Merger Sub ), providing for, among other things, the merger of Merger Sub with and into the Company (the Merger ), with the Company continuing as a wholly owned subsidiary of Akebia. The Merger became effective on December 12, 2018, pursuant to a Certificate of Merger filed with the Secretary of State of the State of Delaware.

Pursuant to the Merger and subject to the terms of the Merger Agreement, each share of Common Stock of the Company issued and outstanding immediately prior to the Merger (other than shares held by Akebia, shares held by Merger Sub, shares held by any subsidiaries of Akebia or the Company (other than the Merger Sub), shares held by the Company as treasury shares, or restricted shares of the Company) was cancelled and converted into the right to receive 0.37433 shares of common stock of Akebia, par value \$0.00001 per share, and cash in lieu of fractional shares.

As a result of the Merger, the Company has terminated the offerings of the Company's securities pursuant to the Prior Registration Statements. In accordance with undertakings made by the Company in the Prior Registration Statements to remove from registration, by means of a post-effective amendment, any of securities that were registered for issuance that remain unsold at the termination of the offering, the Company hereby removes and withdraws from registration all of such securities of the Company registered but unsold under the Prior Registration Statements as of the date hereof.

## SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing these Post-Effective Amendments to the Registration Statements on Form S-3 and has duly caused these Post-Effective Amendments to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge in the Commonwealth of Massachusetts, on December 13, 2018.

Keryx Biopharmaceuticals, Inc.

By: /s/ Nicole R. Hadas

Name: Nicole R. Hadas

Title: President and Secretary (Principal  
Executive Officer)

Pursuant to the requirements of the Securities Act of 1933, these Post-Effective Amendments to the Registration Statements on Form S-3 has been signed by the following person in the capacity and on the date indicated.

Signatures	Capacity	Date
/s/ John P. Butler	Sole Director	December 13, 2018
John P. Butler		